miRNA-212/132 family as a therapeutic target

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9388411
SERIAL NO

14342867

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention refers to inhibitors of microRNAs, particularly of microRNAs miR-212 and/or miR-132 for use in medicine, particularly in the diagnosis, treatment or prevention of cardiac disorders, e.g. cardiac hypertrophy-associated or autophagic disorders, and further refers to isolated nucleic acid molecules, particularly microRNAs miR-212 and/or miR-132 and related sequences, for use in medicine, particularly human medicine, more particularly in the diagnosis, treatment or prevention of disorders involving cardiac atrophy and/or dysfunctional autophagy, e.g. cardiac cachexia.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E VHOFGARTENSTRASSE 8 MUENCHEN 80539
MEDIZINISCHE HOCHSCHULE HANNOVERCARL-NEUBERG-STRASSE 1 HANNOVER 30625

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chowdhury, Kamal Goettingen, DE 3 1
Gupta, Shashi Kumar Hannover, DE 2 1
Thum, Thomas Hannover, DE 34 116
Ucar, Ahmet Heidelberg, DE 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00